Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Federico V. Grossi is active.

Publication


Featured researches published by Federico V. Grossi.


American Journal of Bioethics | 2004

On the Ethics of Facial Transplantation Research

Osborne P. Wiggins; John H. Barker; Serge Martinez; Marieke Vossen; Claudio Maldonado; Federico V. Grossi; Cedric Francois; Michael R. Cunningham; Gustavo Perez-Abadia; Moshe Kon; Joseph C. Banis

Transplantation continues to push the frontiers of medicine into domains that summon forth troublesome ethical questions. Looming on the frontier today is human facial transplantation. We develop criteria that, we maintain, must be satisfied in order to ethically undertake this as-yet-untried transplant procedure. We draw on the criteria advanced by Dr. Francis Moore in the late 1980s for introducing innovative procedures in transplant surgery. In addition to these we also insist that human face transplantation must meet all the ethical requirements usually applied to health care research. We summarize the achievements of transplant surgery to date, focusing in particular on the safety and efficacy of immunosuppressive medications. We also emphasize the importance of risk/benefit assessments that take into account the physical, aesthetic, psychological, and social dimensions of facial disfiguration, reconstruction, and transplantation. Finally, we maintain that the time has come to move facial transplantation research into the clinical phase.


Plastic and Reconstructive Surgery | 2006

Investigation of risk acceptance in facial transplantation.

John H. Barker; Allen Furr; Michael L. Cunningham; Federico V. Grossi; Dalibor Vasilic; Barckley Storey; Osborne P. Wiggins; Ramsey K. Majzoub; Marieke Vossen; Claudio Maldonado; Christopher C. Reynolds; Cedric Francois; Gustavo Perez-Abadia; Johannes Frank; Moshe Kon; Joseph C. Banis

Background: The surgical techniques necessary to transplant a human face are well established, and the early success of human hand transplants suggests that the immunological hurdles of transplanting human facial tissues have largely been overcome. Therefore, it is the ethical barriers that pose the greatest challenge to performing facial transplantation. At the center of the ethical debate is the question, “Do the risks posed by the life-long immunosuppression that a recipient would have to take justify the benefits of receiving a face transplant?” In this study, the authors answer this question by assessing the degree of risk individuals would be willing to accept to receive a face transplant. Methods: To quantitatively assess risks versus benefits in facial transplantation, the authors developed the Louisville Instrument for Transplantation, or LIFT, which contains 237 standardized questions. Respondents in three study populations (healthy individuals, n = 150; organ transplant recipients, n = 42; and individuals with facial disfigurement, n = 34) were questioned about the extent to which they would trade off specific numbers of life-years, or sustain other costs, in exchange for receiving seven different transplant procedures. Results: The authors found that the three populations would accept differing degrees of risk for the seven transplant procedures. Organ transplant recipients were the most risk-tolerant group, while facially disfigured individuals were the least risk tolerant. All groups questioned would accept the highest degree of risk to receive a face transplant compared with the six other procedures. Conclusions: This study presents an empirical basis for assessing risk versus benefit in facial transplantation. In doing so, it provides a more solid foundation upon which to introduce this exciting new reconstructive modality into the clinical arena.


European Journal of Trauma and Emergency Surgery | 2004

Risk Acceptance in Composite Tissue Allotranplantation Reconstructive Procedures

Michael R. Cunningham; Ramsey K. Majzoub; Luis A. Laurentin-Perez; Claudio Maldonado; Joseph C. Banis; Federico V. Grossi; Johannes Frank; John H. Barker; Deepak K. Naidu

AbstractComposite tissue allotransplantation (CTA) has recently emerged as a new therapeutic modality to reconstruct major tissue defects of the face, larynx, and extremities. However, because the risk-versus-benefit ratio for CTA procedures has not yet been defined, the decision as to whether or not to perform these new reconstructive techniques is based on subjective opinions rather than objective data. To address this problem, the authors developed a reliable and valid instrument to objectively assess the relative risk that individuals are willing to accept in order to receive the benefits of various CTA procedures.


Plastic and Reconstructive Surgery | 2006

Neuroregeneration in composite tissue allografts: effect of low-dose FK506 and mycophenolate mofetil immunotherapy.

Bradford L. Cottrell; Gustavo Perez-abadia; Stephen M. Onifer; David S.K. Magnuson; Darlene A. Burke; Federico V. Grossi; Cedric Francois; John H. Barker; Claudio Maldonado

Background: The immunosuppressant FK506 has been reported to increase the rate of peripheral nerve regeneration in nerve crush injury and nerve allograft models. The purpose of this study was to determine whether low doses of FK506 and mycophenolate mofetil had a neuroregenerative effect in revascularized peripheral nerve allografts in a rat hind limb transplantation model. Methods: Wistar Furth rat recipients received limbs from syngeneic Wistar Furth donors (group 1, n = 4) or from allogeneic August X Copenhagen Irish rat donors (group 2, n = 6). Wistar Furth recipients received limbs from August X Copenhagen Irish donors and were treated with FK506/mycophenolate mofetil for 5 months (group 3, n = 7). At the end of the follow-up period, histomorphometric analysis of sciatic and tibial nerves from transplanted and intact hind limbs was conducted. Sciatic and tibial nerves were examined at the level of coaptation and near the neuromuscular junction, respectively. Results: Transplanted limbs in groups 1 and 3 completed the study without rejection, while the limbs in group 2 were rejected within a few days. Sciatic and tibial nerve analysis in groups 1 and 3 limbs showed myelinated axons of various diameters but in significantly fewer numbers than in nontransplanted contralateral nerves. The number and size of myelinated axons of transplanted nerves at corresponding levels were not significantly different between syngeneic and allogeneic (FK506/mycophenolate mofetil–treated) transplants. Conclusions: The authors conclude that long-term neuroregeneration of revascularized peripheral nerves using low-dose FK506/mycophenolate mofetil was similar to that of syngeneic transplants. The occurrence of acute rejection episodes with low-dose FK506/mycophenolate mofetil did not appear to benefit nor impair neuroregeneration.


Transplantation | 2006

Vascularized lymph node transplantation induces graft-versus-host disease in chimeric hosts

Cedric Francois; Pascal C. R. Brouha; Luis A. Laurentin-Perez; Gustavo Perez-Abadia; Federico V. Grossi; John H. Barker; Charles W. Hewitt; Moshe Kon; Rajendra Ramsamooj; Claudio Maldonado

Background. The role of lymph nodes (LNs) in adaptive immune responses has been the subject of extensive research. In previous studies, the surgical removal of lymph nodes from rat hind limbs prevented the development of lethal graft-versus-host disease (GVHD) after allogeneic hind limb transplantation to chimeric recipient rats. The purpose of this study was to establish the role of the cellular fraction versus the microenvironment of LNs in the development of GVHD in this model. Methods. A rat model for vascularized LN transplantation was developed and graft-versus-host responses were compared after: 1) naive ACI LN cells were infused into Wistar-Furth (WF) rats as chimeric recipients (e.g. [ACI→WF]); 2) vascularized WF lymph nodes were transplanted to syngeneic WF recipients; 3) nonvascularized ACI lymph nodes were transplanted to [ACI→WF] chimeric recipients; 4) vascularized ACI lymph nodes were transplanted to [ACI→WF] chimeric recipients. Results. Transplantation of vascularized ACI lymph nodes to [ACI→WF] chimeric recipient rats resulted in severe and sometimes lethal GVHD. In contrast, neither the infusion of purified ACI LN cells nor the transplantation of nonvascularized LNs led to GVHD in chimeric recipients. Conclusions. When introducing allogeneic cells into chimeric recipients, concomitant transplantation of the vascularized LN microenvironment makes a manifest difference between induction and absence of GVHD. This illustrates the important role of the LN microenvironment in adaptive immune responses.


Annals of Plastic Surgery | 2005

Ischemic preconditioning of skeletal muscle : Duration of late-phase protection

Thomas Harralson; Federico V. Grossi; Edwin E. Quan; Taskin Tecimer; Gustavo Perez-Abadia; Gary L. Anderson; John H. Barker; Claudio Maldonado

Background:The time course of the late phase of ischemic preconditioning (IPC) was determined in latissimus dorsi muscle (LDM) flaps using viability and function as the endpoints. Materials and Methods:LDM flaps from Sprague-Dawley rats were allocated into 6 groups. LDMs were preconditioned with 2 30-minute periods of ischemia separated by 10 minutes of reperfusion and subjected to a 4-hour ischemic insult after 24, 48, 72, and 96 hours from IPC. LDMs were evaluated for percent necrosis and muscle contractile function and compared with controls. Results:The late phase of IPC provides significant protection against necrosis up to 72 hours. Conversely, when the end point used was muscle contractile function, the protection only lasted 48 hours. Conclusion:The time course of late-phase protection in skeletal muscle is 2–3 days. Late phase IPC appears to protect muscle flaps during the most critical time period following elevation.


Journal of Hand Surgery (European Volume) | 2006

Investigation of Risk Acceptance in Hand Transplantation

Ramsey K. Majzoub; Michael R. Cunningham; Federico V. Grossi; Claudio Maldonado; Joseph C. Banis; John H. Barker


American Journal of Bioethics | 2004

Response to Selected Commentaries on the AJOB Target Article “On the Ethics of Facial Transplantation Research”

Joseph C. Banis; John H. Barker; Michael R. Cunningham; Cedric Francois; Allen Furr; Federico V. Grossi; Moshe Kon; Claudio Maldonado; Serge Martinez; Gustavo Perez-Abadia; Marieke Vossen; Osborne P. Wiggins


Archive | 2006

Cell-surface decoration with active agents

Claudio Maldonado; Federico V. Grossi; Gustavo Perez-Abadia; William D. Ehringer


Blood | 2016

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

Federico V. Grossi; Pauline Bedwell; Pascal Deschatelets; Lil Edis; Cedric Francois; Patrick J Johnson; Helen J Richardson; Lisa Tan; Carolina Vega; Jason D. Lickliter

Collaboration


Dive into the Federico V. Grossi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

John H. Barker

Goethe University Frankfurt

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge